HOME >> BIOLOGY >> NEWS
AVANT to develop an oral anthrax and plague vaccine for U.S. Department of Defense

This release has been updated as of Monday January 21st.

NEEDHAM, MA (January 22, 2003): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing. AVANT executed the subcontract with DynPort Vaccine Company LLC ("DVC"), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.

"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of AVANT to conduct this development program is an important recognition of the strength of AVANT's vaccine and vector technologies for accomplishing these aims."

"This contract is very important to AVANT since it provides non-dilutive funding to the company and it means that AVANT now has over two years of cash and cash equivalents on hand," Dr. Ryan concluded.

Senator Edward M. Kennedy (D-MA), Ranking Dem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-281-2413
Kureczka/Martin Associates
22-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Wisconsin scientists develop quick botox test
5. Bronfenbrenner book sums up human development
6. Researchers develop fast track way to discover how cells are regulated
7. DuPont developing new protective suits for military, first responders
8. OutFoxed! New research may redefine late-stage cardiac development
9. Computer scientists at UH developing nurturing computers
10. Disease diagnosis, drug development focus of UH profs biochip research
11. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/14/2016)... MELBOURNE, Florida , March 14, 2016 ... on the growing mobile commerce market, announces the airing of ... York channels starting the week of March 21 st . ... and CNBC, including its popular Squawk on the Street show. ... company focused on the growing mobile commerce market, announces the ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... ... used in spinal surgical procedures, today announced the completion of a significant transaction ... for current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
Breaking Biology Technology:
Cached News: